logo
Share SHARE
FONT-SIZE Plus   Neg

Novartis: Gilenya Effective Against 4 Measures Of Disease Activity In MS

Swiss drugmaker Novartis AG (NVS: Quote) Monday said that two new analyses from the Phase III Transforms study demonstrated how its Gilenya (fingolimod) was effective against all four key measures of disease activity in multiple sclerosis - brain volume loss, lesion activity, relapse rates and disability progression.

Improvements were seen in patients who switched from standard interferon treatment to Gilenya within 12 months of the switch and up to the end of the 4.5 year extension study.

MS is a chronic neuroinflammatory and neurodegenerative illness where disease activity leads to accumulation of disability and loss of brain tissue.

The new analysis evaluated the association between measures of disease activity in the first year of therapy and long-term clinical outcomes. Gilenya increased the proportion of patients who were disease-free by almost 50 percent when switched from interferon to Gilenya in year-1 to year-2.

Patients who had disease-activity at the end of the first year were significantly less likely to remain clinically disease free during the following 3.5 years of the extension study.

A separate post-hoc analysis showed that patients who had disease-activity in the year prior to entering the study, despite prior treatment with a disease-modifying treatment, experienced sustained benefit on Gilenya with a lower annualized relapse rate compared to those who were given interferon for the first year.

The analyses were presented at the 23rd meeting of the European Neurological Society or ENS in Barcelona.

Dr. Timothy Wright, Global Head Development, Novartis Pharmaceuticals, said, "Data have consistently shown that treatment with Gilenya leads to more patients staying disease free, compared to standard interferon treatment."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The Federal Communications Commission on Thursday voted along expected lines to adopt new rules to monitor Internet service providers to protect open access and innovation, pacifying consumers and tech companies like Netflix, while creating heartburn for cable and telecom companies. Google Inc. (GOOG, GOOGL) has made a $300 million investment in a fund that will finance residential power projects. SolarCity Corp. (SCTY) Thursday said it has created a fund expected to finance $750 million in residential solar projects with Google investing about $300 million. The new fund... As consumers' choice for mobile payment surges, with smartphone makers, Internet companies and credit card firms in the fray, no clear winner is yet to emerge in this financial landscape that is set to flourish and chisel the fate of businesses, shows a survey commissioned by Placecast.
comments powered by Disqus
RELATED NEWS
Trade NVS now with 
Follow RTT